1. Registration

  2. Plenary session: Global regulatory trends

    Emma Chynoweth Emma Chynoweth
    Founder, Ocki Sustainability
    Cristina Garcia Cristina Garcia
    Project Manager, Knoell Iberia S.L.
  3. Substance evaluations and appeals before the Board of Appeal

    • Dossier compliance vs Substance evaluation
    • Legal implications / Criteria for legal challenges
    • Board of Appeal decisions
    Claudio Mereu Claudio Mereu
    Partner, EU Regulatory, Fieldfisher LLP, Belgium
  4. Refreshments

  5. The benefits of using bioelution testing in hazard characterisation and classification of complex mixtures

    • Hazard classification of complex inorganic materials – issues and challenges
    • The MeClas tool
    • Bioelution testing – principles and applications (with examples)
    • Regulatory acceptance of the concept – current status/ongoing work
    Kevin Klipsch Kevin Klipsch
    Senior Registration Manager, EBRC Consulting GmbH, Germany
  6. Lunch

  7. Ineris: Toxicology and REACH

    In the context of REACH regulation and its implementation, our testing capabilities and expertise permit a complete offer for the registration of a chemical. In particular, INERIS provides toxicological services within a GLP-compliant platform of 1000 m² dedicated to in vivo rodent experiments, including the performance of a battery of in vivo assays, following OECD Test Guidelines (e.g. acute toxicity studies, inhalation toxicology (OECD TG 436, 412, 413) and reproductive toxicology, including neurologic endpoints (OECD TG 422, 443).

    Anne Braun Anne Braun
    Head of Experimental Toxicology Unit, INERIS
  8. Stream 1: Europe (Biocidal Product Regulation)
  9. Biocidal product authorisations strategies and issues under the BPR

    • Which tools are available under the BPR to achieve product authorisation (families, same, consortia) and how can these tools be used to create the best authorisation strategy?
    • What are some of the questions companies should ask themselves to determine the appropriate authorisation strategy?
    • How will the Endocrine Disruption criteria and Brexit affect biocidal product authorisation strategies?
    Eléonore Mullier Eléonore Mullier
    Partner, Steptoe LLP, Belgium
    Hannah Widemann Hannah Widemann
    Senior Associate, Chemical and Life Sciences, Steptoe & Johnson LLP
  10. Refreshments

  11. Biocides: The good, the bad, and the ugly

    • Where the biocides legislation currently is
    • The impact it is having on industry
    • Expected upcoming changes and challenges
    Eleanor Grimes Eleanor Grimes
    Regulatory Specialist, UL
  12. Close of Day One

View previous day

/ Next stream